Existing research shows that semaglutide can: Improve insulin resistance Promote a healthy body weight Reduce inflammation Lower the risk of certain diseases, such as heart disease However, many of these findings have been observed in people with Type 2 diabetes, obesity, and cardiovascular diseases
Patients with a history of pancreatitis, thyroid cancer, or medullary thyroid carcinoma should avoid both agents
A minimum of two weeks, with four weeks being ideal for most people
The effects of mitochondrial iron homeostasis on cofactor specificity of superoxide dismutase 2
Patients using Foundayo saw a significant 12.4% reduction in weight in trials, providing another option for those preferring oral GLP-1 medications
This multidisciplinary approach ensures that reduced dietary intake from GLP-1 RA therapy does not inadvertently compromise microbiome composition, which is essential for sustaining the anti-inflammatory benefits of treatment